3 options
Current Immunotherapeutic Strategies in Cancer / edited by Matthias Theobald.
LIBRA RC261 .R35 v.1 (1965)-v.5 (1966), v.7 (1966)-v.98 (1985), v.100 (1986)-v.121 (1991), v.123 (1991)-v.126 (1993), v.128 (1993)-v.158 (2000); v.13:2nd ed. (1976) 1969
Available from offsite location
Holman Biotech Commons - Periodicals Per. v.159 (2002)-184,186,188-189,191-192,194-196
Mixed Availability
Levy Dental Medicine Library - Stacks RC261 .R35 149
Mixed Availability
- Format:
- Book
- Series:
- Medicine (Springer-11650)
- Recent results in cancer research 0080-0015 ; 214.
- Recent Results in Cancer Research, 0080-0015 ; 214
- Language:
- English
- Subjects (All):
- Oncology.
- Immunology.
- Local Subjects:
- Oncology.
- Immunology.
- Physical Description:
- 1 online resource (V, 187 pages).
- Edition:
- First edition 2020.
- Contained In:
- Springer eBooks
- Place of Publication:
- Cham : Springer International Publishing : Imprint: Springer, 2020.
- System Details:
- text file PDF
- Summary:
- This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient's cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.
- Contents:
- Current Development of Monoclonal Antibodies in Cancer Therapy
- Clinical Experience with Bispecific T-Cell Engagers
- Advances and challenges of CAR-modified T cells in clinical trials
- Targeting Cancer with Genetically Engineered TCR-T Cells
- Tailored Vaccines Based on Patient's Cancer Mutanome
- Next-Generation Checkpoint Inhibitors and Immune Agonists.
- Other Format:
- Printed edition:
- ISBN:
- 978-3-030-23765-3
- 9783030237653
- Access Restriction:
- Restricted for use by site license.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.